Crossmark Global Holdings Inc. Acquires 977 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

Crossmark Global Holdings Inc. boosted its holdings in BeiGene, Ltd. (NASDAQ:BGNE) by 25.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,829 shares of the company’s stock after acquiring an additional 977 shares during the period. Crossmark Global Holdings Inc.’s holdings in BeiGene were worth $1,084,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Driehaus Capital Management LLC acquired a new position in BeiGene in the 2nd quarter valued at $1,168,000. Swedbank AB acquired a new position in BeiGene in the 1st quarter valued at $2,596,000. M&G Plc acquired a new position in BeiGene in the 1st quarter valued at $29,649,000. The Manufacturers Life Insurance Company grew its holdings in BeiGene by 8.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 50,262 shares of the company’s stock valued at $7,171,000 after buying an additional 3,915 shares in the last quarter. Finally, Van ECK Associates Corp grew its holdings in BeiGene by 8.9% in the 2nd quarter. Van ECK Associates Corp now owns 95,577 shares of the company’s stock valued at $13,636,000 after buying an additional 7,816 shares in the last quarter. Institutional investors own 48.55% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Citigroup increased their target price on BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. TD Cowen increased their target price on BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a research report on Wednesday. JMP Securities initiated coverage on BeiGene in a research report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 target price for the company. JPMorgan Chase & Co. increased their target price on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, October 22nd. Finally, StockNews.com upgraded BeiGene from a “hold” rating to a “buy” rating in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $247.07.

BeiGene Price Performance

Shares of BGNE opened at $193.29 on Friday. BeiGene, Ltd. has a 1 year low of $126.97 and a 1 year high of $248.16. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.98 and a quick ratio of 1.75. The company has a market capitalization of $18.83 billion, a price-to-earnings ratio of -23.68 and a beta of 0.63. The business has a 50-day moving average of $212.91 and a 200-day moving average of $181.72.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). BeiGene had a negative return on equity of 25.15% and a negative net margin of 25.94%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.26 million. During the same quarter last year, the business earned $2.01 earnings per share. BeiGene’s revenue was up 28.2% compared to the same quarter last year. As a group, equities research analysts anticipate that BeiGene, Ltd. will post -5 earnings per share for the current year.

Insider Buying and Selling at BeiGene

In related news, insider Titus B. Ball sold 137 shares of BeiGene stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total transaction of $26,021.78. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Chan Henry Lee sold 1,202 shares of BeiGene stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $237.10, for a total value of $284,994.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,070 shares of company stock valued at $4,901,050. Company insiders own 7.43% of the company’s stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.